(0.17%) 5 100.25 points
(0.55%) 38 594 points
(0.43%) 17 725 points
(0.38%) $79.25
(0.00%) $2.04
(-0.04%) $2 308.60
(-0.07%) $26.81
(0.42%) $966.60
(-0.05%) $0.932
(-0.18%) $10.97
(-0.11%) $0.797
(0.69%) $91.76
Live Chart Being Loaded With Signals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...
Stats | |
---|---|
今日成交量 | 169 171 |
平均成交量 | 328 385 |
市值 | 80.25M |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.13 |
ATR14 | $0.00200 (1.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-25 | Pershing Edward | Buy | 37 752 | Series D-1 Convertible Preferred Stock |
2024-04-25 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-19 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-11 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 17 761 544 | Sell: 0 |
Provectus 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Provectus 财务报表
Annual | 2023 |
营收: | $557 710 |
毛利润: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2023 |
营收: | $557 710 |
毛利润: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2022 |
营收: | $989 042 |
毛利润: | $925 264 (93.55 %) |
EPS: | $-0.00850 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.0100 |
Financial Reports:
No articles found.
Provectus
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。